Opinion

Video

Clinical Pearls for Clinicians Treating Fibromyalgia

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

This is a video synopsis/summary of a panel discussion involving Philip J. Mease, MD.

Fibromyalgia may raise concerns for physicians regarding time consumption and emotional burden. Addressing these concerns requires upfront communication, explaining the neurobiology behind fibromyalgia to reduce stigma, particularly associated with psychological perceptions. With improved treatment approaches, managing fibromyalgia becomes more rewarding, especially when patients respond well to their treatment regimen. When patients have comorbid conditions, such as autoimmune diseases like rheumatoid arthritis or lupus, it's crucial to control both conditions concurrently. Employing current medications, biologics, and targeted synthetic disease-modifying drugs to manage inflammation and symptoms is essential. Simultaneously, acknowledging the presence of central sensitization or fibromyalgia is vital, fostering acceptance through patient-friendly language. Using terms like "central sensitization" can mitigate the stigma around fibromyalgia. Collaboratively pursuing nonpharmacological approaches alongside prescribed treatments enhances patient acceptance and makes the overall treatment approach more rewarding for both the physician and the patient.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.